DK Life Science Co., Ltd. (KOSDAQ:303810)
South Korea · Delayed Price · Currency is KRW 8,980.00
-90.00 (-0.99%)
Jul 18, 2025, 3:30 PM KST
DK Life Science Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Operating Revenue | 133,299 | 131,816 | 120,161 | 107,234 | 102,668 | 109,583 | Upgrade |
Other Revenue | -0 | - | -0 | - | - | -0 | Upgrade |
| 133,299 | 131,816 | 120,161 | 107,234 | 102,668 | 109,583 | Upgrade | |
Revenue Growth (YoY) | 24.31% | 9.70% | 12.05% | 4.45% | -6.31% | 11.12% | Upgrade |
Cost of Revenue | 104,407 | 103,241 | 94,909 | 85,063 | 80,826 | 86,428 | Upgrade |
Gross Profit | 28,892 | 28,575 | 25,253 | 22,171 | 21,842 | 23,155 | Upgrade |
Selling, General & Admin | 13,599 | 13,995 | 13,795 | 13,833 | 13,700 | 11,115 | Upgrade |
Research & Development | 1,585 | 1,466 | 1,140 | 1,014 | 1,017 | 1,217 | Upgrade |
Other Operating Expenses | 280.27 | 278.48 | 289.6 | 258.83 | 256.82 | 182.93 | Upgrade |
Operating Expenses | 16,743 | 16,659 | 16,723 | 15,941 | 15,045 | 14,727 | Upgrade |
Operating Income | 12,149 | 11,916 | 8,530 | 6,230 | 6,797 | 8,428 | Upgrade |
Interest Expense | -2,449 | -3,395 | -4,994 | -3,620 | -2,441 | -1,379 | Upgrade |
Interest & Investment Income | 60.85 | 54.74 | 98.3 | 152.55 | 69.84 | 35.32 | Upgrade |
Currency Exchange Gain (Loss) | -1,090 | -1,687 | -124.83 | -44.41 | -212.04 | -17.97 | Upgrade |
Other Non Operating Income (Expenses) | -2,453 | -2,195 | 2,241 | 2,241 | -981.23 | -692.53 | Upgrade |
EBT Excluding Unusual Items | 6,219 | 4,694 | 5,750 | 4,959 | 3,232 | 6,373 | Upgrade |
Gain (Loss) on Sale of Investments | 115.41 | 49.07 | -1,670 | 321.86 | 3,236 | 347.7 | Upgrade |
Gain (Loss) on Sale of Assets | 82.54 | 9.63 | 749.93 | - | -34.43 | - | Upgrade |
Pretax Income | 6,417 | 4,753 | 4,830 | 5,281 | 6,433 | 6,721 | Upgrade |
Income Tax Expense | 2,615 | 2,508 | 663.28 | 1,041 | 575.2 | 2,266 | Upgrade |
Net Income | 3,802 | 2,245 | 4,167 | 4,239 | 5,858 | 4,455 | Upgrade |
Net Income to Common | 3,802 | 2,245 | 4,167 | 4,239 | 5,858 | 4,455 | Upgrade |
Net Income Growth | -10.31% | -46.13% | -1.71% | -27.63% | 31.49% | -29.05% | Upgrade |
Shares Outstanding (Basic) | 14 | 13 | 11 | 1 | 1 | 1 | Upgrade |
Shares Outstanding (Diluted) | 14 | 13 | 11 | 1 | 1 | 1 | Upgrade |
Shares Change (YoY) | 1125.53% | 14.52% | 900.58% | 0.01% | -2.05% | 2.09% | Upgrade |
EPS (Basic) | 277.14 | 175.00 | 372.00 | 3787.00 | 5233.00 | 3980.00 | Upgrade |
EPS (Diluted) | 277.14 | 175.00 | 372.00 | 3787.00 | 5233.00 | 3898.00 | Upgrade |
EPS Growth | -92.68% | -52.96% | -90.18% | -27.63% | 34.25% | -30.50% | Upgrade |
Free Cash Flow | 3,166 | 6,455 | -9,398 | -20,287 | -24,739 | -15,026 | Upgrade |
Free Cash Flow Per Share | 230.75 | 503.21 | -839.06 | -18122.49 | -22100.17 | -13147.89 | Upgrade |
Gross Margin | 21.68% | 21.68% | 21.02% | 20.68% | 21.27% | 21.13% | Upgrade |
Operating Margin | 9.11% | 9.04% | 7.10% | 5.81% | 6.62% | 7.69% | Upgrade |
Profit Margin | 2.85% | 1.70% | 3.47% | 3.95% | 5.71% | 4.06% | Upgrade |
Free Cash Flow Margin | 2.38% | 4.90% | -7.82% | -18.92% | -24.10% | -13.71% | Upgrade |
EBITDA | 18,146 | 17,698 | 11,813 | 8,691 | 9,181 | 10,517 | Upgrade |
EBITDA Margin | 13.61% | 13.43% | 9.83% | 8.11% | 8.94% | 9.60% | Upgrade |
D&A For EBITDA | 5,997 | 5,782 | 3,283 | 2,461 | 2,385 | 2,089 | Upgrade |
EBIT | 12,149 | 11,916 | 8,530 | 6,230 | 6,797 | 8,428 | Upgrade |
EBIT Margin | 9.11% | 9.04% | 7.10% | 5.81% | 6.62% | 7.69% | Upgrade |
Effective Tax Rate | 40.75% | 52.77% | 13.73% | 19.72% | 8.94% | 33.72% | Upgrade |
Advertising Expenses | - | 1,866 | 2,344 | 1,748 | 1,552 | 1,315 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.